Suzuken
9987.TTSE PRIMEWholesale Trade
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.49T | ¥2.40T | ¥2.39T | ¥2.31T | ¥2.24Tr | ¥2.13T |
| Operating income | ¥36.4bn | ¥37.1bn | ¥34.9bn | ¥32.6bn | ¥20.1bnr | ¥9.2bn |
| Ordinary income | ¥39.7bn | ¥38.8bn | ¥38.4bn | ¥36.4bn | ¥23.4bn | ¥18.3bn |
| Net income (owners) | ¥38.1bn | ¥34.5bn | ¥29.0bn | ¥20.3bn | ¥14.4bn | ¥7.9bn |
| Total assets | ¥1.16T | ¥1.11T | ¥1.23T | ¥1.15T | ¥1.14T | ¥1.11T |
| Net assets / equity | ¥416.0bn | ¥407.4bn | ¥416.4bn | ¥411.5bn | ¥418.1bn | ¥417.9bn |
| Operating cash flow | ¥33.6bn | −¥65.1bn | ¥87.2bn | ¥37.3bn | ¥9.5bn | ¥15.6bn |
| EPS (basic) | ¥545.54 | ¥454.58 | ¥357.88 | ¥236.47 | ¥163.19 | ¥88.52 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 67 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 67 figures · EDINET |
23 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| The Community Healthcare And Nursing Care Support Business | ¥93.9bn | ¥1.5bn |
| The Healthcare Product Development Business | ¥11.9bn | ¥830m |
| The Healthcare Related Services Business | ¥24.6bn | ¥1.3bn |
| The Pharmaceutical Distribution Business | ¥2.35T | ¥31.5bn |
| The Specialty Drug Contract Distribution Business | ¥6.8bn | ¥1.2bn |
| Total | ¥2.49T | ¥36.3bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.